Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study.
about
Selective delivery of therapeutic agents for the diagnosis and treatment of cancer.Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts.Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells.Targeting Hypoxia to Improve Non-Small Cell Lung Cancer Outcome.
P2860
Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Tirapazamine with cisplatin an ...... ng cancer: a phase I/II study.
@en
type
label
Tirapazamine with cisplatin an ...... ng cancer: a phase I/II study.
@en
prefLabel
Tirapazamine with cisplatin an ...... ng cancer: a phase I/II study.
@en
P356
P1433
P1476
Tirapazamine with cisplatin an ...... ng cancer: a phase I/II study.
@en
P2093
Michel Gatineau
P304
P356
10.3816/CLC.2005.N.008
P407
P577
2005-03-01T00:00:00Z